ASCO's Guideline Update Includes Oncotype DX in Early-Stage Breast Cancer

The American Society of Clinical Oncology (ASCO) has updated its 2022 guideline for biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer to include the Oncotype DX Breast Recurrence Score^® test. This test is recommended for use in postmenopausal patients with up to three positive axillary lymph nodes, irrespective of clinical risk.

For more information, read Exact Sciences' announcement and the ASCO guideline update.

Posted 5/2/2022